Vor Biopharma Inc.

VOR

Explore Our Financial Data > Companies > Vor Biopharma Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	VOR
CIK	0001817229
SIC	2836
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Biological Products, Except Diagnostic Substances

Contact

Address	100 CAMBRIDGEPARK DRIVE, SUITE 101, CAMBRIDGE, MA, 02140
Website	vorbio.com
Phone	617-655-6580
CEO	Bob Ang
Employees	140

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	$-118.60 million
Net Income	$-118.60 million
Net Income to Common	$-118.60 million
EPS	$-1.51

View All

Balance Sheet

Cash	$50.05 million
Assets	$109.31 million
Liabilities	$43.24 million
Common Equity	$66.07 million
Liabilities & Equity	$109.31 million

View All

Cash Flow Statement

Net Income	$-118.60 million
Cash From Operating Activities	$-100.26 million
Cash From Investing Activities	$52.65 million
Cash From Financing Activities	$52.69 million
Change in Cash	$5.08 million

View All

Calculations

NOPAT	$-85.50 million
EBITDA	$-119.10 million
Price to Earnings	N/A
Price to Book	$4.54
ROE	-125.43%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of June 26, 2025, the Board of Directors granted Jean-Paul Kress, the Company’s Chief Executive Officer, an option to purchase 83,296,638 shares of Vor Bio’s common stock in connection with the commencement of his employment. The foregoing stock option was granted as a material inducement to employm

Article Link

Sector Update: Health Care Stocks Higher Late Afternoon

Health care stocks rose late Monday afternoon with the NYSE Health Care Index up 0.4% and the Health

Article Link

Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why

The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.

Article Link

Sector Update: Health Care Stocks Edge Higher Late Afternoon

Health care stocks edged up late Thursday afternoon, with the NYSE Health Care Index rising 0.2% and

Article Link

Update: Vor Biopharma Shares Rally After Naming New CEO, Licensing Autoimmune Drug From RemeGen

(Updates with stock move in the headline and first paragraph.) Vor Biopharma (VOR) shares were tr

Article Link